Latest quarter
Bristol Myers Squibb reported Q3 FY2026 revenue of $13.1 billion, above the $12.6 billion consensus, and adjusted EPS of $1.35, above the $1.21 consensus. Revenue rose from $12.2 billion a year earlier, while diluted EPS fell to $1.05 from $1.08.
In its filing, the company attributed revenue growth primarily to higher demand and average net selling prices across its growth portfolio and for Eliquis, partly offset by generic competition elsewhere in the legacy portfolio. The filing said Eliquis revenue increased 25% in the quarter, while Revlimid revenue fell 47% as generics reduced U.S. demand.
The filing attributed the decline in GAAP EPS primarily to higher one-time acquired research and development charges and the expiration of diabetes-product royalty income, partly offset by lower amortization and higher revenue. Bristol Myers Squibb reported gross margin of 68.3%, down from 71.9% a year earlier, and operating margin of 19.4%, down from 25.5%. Free cash flow was $3.8 billion, compared with $6.0 billion a year earlier.
| Q3 FY2026 | Q3 FY2025 | Change | |
|---|---|---|---|
| Revenue | $13.1 billion | $12.2 billion | 6.93% |
| Diluted EPS | $1.05 | $1.08 | −2.49% |
| Gross margin | 68.3% | 71.9% | −3.6 percentage points |
| Operating margin | 19.4% | 25.5% | −6.1 percentage points |
| Free cash flow | $3.8 billion | $6.0 billion | −36.0% |
| Against the consensus | Reported | Consensus | Result |
|---|---|---|---|
| Adjusted EPS | $1.35 | $1.21 | Beat by 11.6% |
| Revenue | $13.1 billion | $12.6 billion | Beat by 4.07% |
Adjusted EPS is the figure the consensus estimates, not the GAAP EPS above.
What management said on the call
Chief Financial Officer David Elkins said the growth portfolio’s revenue rose 12% to $7.7 billion in the quarter, with several medicines delivering double-digit growth. Chief Executive Officer Chris Boerner said eight growth-portfolio medicines were each generating annualized sales above $1 billion based on the quarter’s sales.
Elkins said Eliquis revenue reached approximately $4.7 billion, helped by net price, demand and market-share gains. He said growth in Eliquis more than offset generic-entry declines across the rest of the legacy portfolio. In its filing, Bristol Myers Squibb said its U.S. Eliquis list-price reduction resulted in higher realized average net selling prices because rebates were lower.
For cancer treatment Opdivo, Elkins attributed a revenue decline primarily to patients converting to Opdivo Qvantig in the U.S. and Europe. He said Qvantig generated $334 million in quarterly revenue and was annualizing above $1.3 billion. Elkins said product mix and, to a lesser extent, a one-time contract termination expense affected gross margin. He also said the productivity initiative was reducing expenses while preserving flexibility to invest in growth opportunities.
Looking to the fourth quarter, Elkins said European loss of exclusivity would affect Eliquis sales, partly offset by continued U.S. growth. He said Cobenfy’s sequential revenue reflected inventory destocking that offset increased demand, and he anticipated revenue would more closely track prescription volume going forward.
Asked about 2027, Elkins said he anticipated an Eliquis revenue step-down and that the company was on track to achieve $2 billion of productivity efficiencies by the end of 2027. Boerner said business development remained a capital-allocation priority, with potential opportunities assessed for scientific and strategic fit.
On the pipeline, Boerner said the admilparant trial in idiopathic pulmonary fibrosis met its primary endpoint at the 60 mg dose and that Bristol Myers Squibb would discuss results with regulators. The filing said the 120 mg dose slowed the decline in lung function but did not achieve statistical significance. On the call, Cristian Massacesi said the company had voluntarily paused its ZolaCell clinical program to review clinical data and had identified a change in reagent selection and activation as the root cause of an issue.
Guidance
Bristol Myers Squibb raised its FY2026 non-GAAP revenue guidance to approximately $49.75 billion to $50.25 billion from approximately $49.0 billion to $50.0 billion. The company now expects non-GAAP EPS of $6.35 to $6.55, compared with its previous range of $6.75 to $7.00.
Elkins said the new EPS range includes a 58 cents per share impact from acquired research and development charges and licensing income. He said the midpoint would otherwise have increased by approximately 15 cents per share.
| Metric | For | Guide | Previous guide | Change |
|---|---|---|---|---|
| Operating expenses, Strategic Productivity Initiative | FY2027 | $2.0 billion | — | New |
| Revenue, Cobenfy | Q4 FY2026 | Bristol Myers Squibb expects Cobenfy revenue growth to continue and track prescription growth in Q4 2026. | — | — |
| Revenue, Eliquis US | Q4 FY2026 | Bristol Myers Squibb expects continued U.S. Eliquis revenue growth in Q4 2026. | — | — |
| Revenue growth, Eliquis | FY2026 | 20.0%–25.0% | — | New |
| Revenue growth, Legacy Portfolio | FY2026 | −5.00%–−3.00% | — | New |
| EPS, non-GAAP | FY2026 | $6.35–$6.55 | — | New |
| Revenue, Eliquis | FY2026 | Bristol Myers Squibb expects worldwide Eliquis revenue to increase in FY2026 compared with FY2025. | — | — |
| Revenue, non-GAAP | FY2026 | $49.8 billion–$50.3 billion | $49.0 billion–$50.0 billion | Raised |
| Revenue growth, Eliquis Worldwide | FY2026 | 20.0%–25.0% | — | New |
| EPS, non-GAAP | FY2026 | $6.75–$7.00 | — | — |
| Tax rate, non-GAAP | FY2026 | 18.0% | — | New |
| Operating expenses, non-GAAP | FY2026 | $16.5 billion | — | New |
| Gross margin, non-GAAP | FY2026 | 69.0%–70.0% | — | New |
| Market share, Qvantig US | Next 2 years | 30.0%–40.0% | — | New |